NCT03136640View on ClinicalTrials.gov

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 26, 2017

Primary Completion Date

September 5, 2019

Study Completion Date

September 5, 2019

Conditions
Castration-resistant Prostate Cancer
Interventions
DRUG

ModraDoc006/r

Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets

Trial Locations (4)

1066CX

Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam

6525 GA

Radboud University Medical Center, Nijmegen

3015 CE

Erasmus Medical Center, Rotterdam

3508 GA

University Medical Center Utrecht, Utrecht

Sponsors
All Listed Sponsors
collaborator

The Netherlands Cancer Institute

OTHER

lead

Modra Pharmaceuticals

INDUSTRY

NCT03136640 - ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter